RxDoctor Payments DataLook up a doctor →

Bryan Ferroni, DO

Pulmonary Disease · Williamstown, NJNPI 1508836339

Payments from drug & device makers

$37,685in general payments, 2019–2025

Across 872 payments — averaging $43.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Enterprises LLC$15K
  • Mallinckrodt Hospital Products Inc.$11K
  • AstraZeneca$3K
  • GSK$2K
  • Mylan Specialty L.p.$1K
  • Sanofi$969
  • plus $6K from 36 others

What the payments were for

  • Speaking & faculty fees$25,12567%
  • Food & beverage$12,37733%
  • Education$1840%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$37,685 in reported general payments places this provider in the 90th percentile of 472 pulmonary disease providers in New Jersey.

See all pulmonary disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$150,062
Medicare patients
507
Services billed
1,378

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CortrophinCorticotropin13$420,088
Trelegy ElliptaFluticasone/Umeclidin/Vilanter404$399,337
XolairOmalizumab24$131,515
Prolastin CAlpha-1-Proteinase Inhibitor13$119,699
Dupixent SyringeDupilumab27$103,082
Breo ElliptaFluticasone/Vilanterol160$102,773
FasenraBenralizumab17$94,089
Breztri AerosphereBudesonide/Glycopyr/Formoterol106$91,689
EliquisApixaban79$72,519
TezspireTezepelumab-Ekko12$49,243
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr57$41,198
XareltoRivaroxaban19$24,682
Arnuity ElliptaFluticasone Furoate56$21,477
SymbicortBudesonide/Formoterol Fumarate62$20,809
Fluticasone-SalmeterolFluticasone Propion/Salmeterol94$16,133

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta$1,593$580,666706 claims
AstraZenecaFasenra, Breztri Aerosphere, Tezspire, Symbicort$2,838$255,830197 claims
Grifols USA, LLCProlastin C$194$119,69913 claims
PfizerEliquis$14$72,51979 claims
Johnson & JohnsonXarelto$13$24,68219 claims
Boehringer IngelheimSpiriva Respimat$375$15,47915 claims
MerckDulera$29$15,21526 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$69$6,44113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 472 pulmonary disease providers in New Jersey.

Other pulmonary disease in Williamstown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →